Serum tumor markers in chronic liver disease

Neoplasma

Volumn 43, Issue 1, 1996, Pages 17-21

  Kadayifci, A ^a   Simsek, H ^a   Savas, M C ^a   Toppare, M ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

CA 125; CA 19 9; chronic active hepatitis; cirrhosis; tumr markers

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 19-9 ANTIGEN; TUMOR MARKER;

ARTICLE; BLOOD LEVEL; CHRONIC LIVER DISEASE; CONTROLLED STUDY; FEMALE; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE;

EID: 0029876605     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. ABALEV, G.I.: AFP in oncogenesis and its association with malignant tumors. Adv. Cancer, Res., 14, 1971, 295-358.
2. ALBERT, M.B., STEINBERG, W.M., HENRY, J.P.: Elevated serum levels of tumor marker CA 19-9 in acute cholangitis. Dig. Dis. Sci., 33, 1988, 1223-1225.
3. ATKINSON, B., ERNST, C., HERLYN, M.: Gastrointestinal cancer associated antigen in immunoperoxidase assay. Cancer Res., 42, 1982, 4820-4823.
4. BATES, S.E.: Clinical applications of serum tumor markers. Ann. Int. Med., 115, 1991, 623-638.
5. BATES, S.E., LONGO, D.L.: Use of serum tumor markers in cancer diagnosis and management. Semin. Oncol., 14, 1987, 102-138.
6. BERGMANN, J.F., BEAUGRAND, M., LABADIE, H., BIDART, J.M., BOHUON, C.: CA 125 in ascitic liver diseases. Clin. Chim. Acta, 155, 1986, 163-166.
7. BERGMANN, J.F., BIDARIT, J.M., GEORGE, M., BEAUGRAND, M., LEVY, V.G., BOHUON, C.: Elevation of CA 125 in patients with benign and malignant ascites. Cancer, 59, 1987, 213-217.
8. BLOOMER, J.R., WALDMAN, T.A., MCINTIRE, K.R., KLATSKIN, G.: AFP in nonneoplastic hepatic disorders. JAMA, 233, 1975, 38-41.
9. BUAMAH, P.K., CORNELL, C., VENABLES, C.W., SKILLEN, A.W.: An initial appraisal of the value of serum CA 19-9 levels in patients with pancreatic cancer. Eur. J. Cancer. Clin. Oncol., 23, 1987, 87-91.
10. CASES, A., FILELLA, X., MOLINA, R., BALLESTA, A.M., LOPEZ-PEDRET, J.: Revert. Tumor markers in chronic renal failure and hemodialysis patients. Nephron, 57, 1991, 183-186.
11. GITLIN, D., BOESMAN, M.: Sites of serum AFP synthesis in the human and rat. J. Clin. Invest., 46, 1967, 1010-1016.
12. HAGLUND, C., KUUSELA, P., ROBERTS, P., JALANKO, H.: Tumor marker CA 125 in patients with digestive tract malignancies. Scand. J. Clin. Lab. Invest., 51, 1991, 265-270.
13. HANSEN, H.J., SNYDER, L.J., MILLER, E.: CEA assay. A laboratory adjunct in the diagnosis and managament of cancer. J. Hum. Pathol., 5, 1974, 139-147.
14. HENNEBERRY, M.D., ENGEL, G., GRAYHACK, J.T.: Acid phosphatase. Urol. Clin. North. Am., 6, 1979, 629-641.
15. JACOPS, E.L., HASKELL, C.M.: Clinical use of tumor markers in oncology. Curr. Probl., Cancer, 6, 1991, 301-338.
16. KABAWAT, S.E., BAST, R.C., BHAN, A.K., WELCH, W.R., KNAPP, R.C., COLVIN, R.B.: Tissue distribution of a coelomic epithelium related antigen recognized by the monoclonal antibody OC 125. Int. J. Gynecol. Pathol., 2, 1983, 275-285.
17. KADAYIFCI, A., ÖZYILKAN, E., SIMSEK, H., SIVRI, B., KAYHAN, B., OZKUYUMCU, C., TELATAR, H.: The elevation of serum tumor markers CA 19-9 and CA 125 in chronic liver disease type B and C. Eur. J. Cancer. Suppl., 6, 29A, 1993, 245.
18. KNODEL, R.G., ISHAK, K.G., CRAIG, R., KAPLOWITZ, N., KIERNAN, T.W.: Histology activity index for numerical scoring and assessment of asymptomatic chronic active hepatitis liver biopsies. Gastroenterology, 79, 1980, 1031.
19. MINTON, J.P., CHEVINSKY, A.: Present status of serum markers. Semin. Surg. Oncol., 5, 1989, 426-435.
20. NAGASUE, N., YUKAYA, H., CHANG, Y.C.: Serum ferritin level after resection of hepatocellular carcinoma. Cancer, 57, 1986, 1820-1823.
21. ÖZYILKAN, E., SIMSEK, H., OZDEMIR, O., SIVRI, B., KIRAZLI, S., TELATAR, H.: Plasminogen activator mhibitor-2 and alpha-fetoprotein in various liver disease states. Thromb. Haemost., 68, 1992, 374.
22. PAYDAS, S., SARGIN, Ö., ÖZBEK, S., GÜRBÜZ, E.: Ferritin levels in malignant effusions: A useful marker? Eur. J. Cancer, 26, 1990, 919.
23. PLESKOW, D.K., BERGER, H.J., GYVES, J., ALLEN, E., MCLEAN, A., PODOLSKY, D.K.: Evaluation of a serologic marker, CA 19-9, in the diagnosis of pancreatic cancer. Ann. Intern. Med., 110, 1989, 704-709.
24. SAFI, F., ROSCHER, R., BEGER, H.G.: The clinical relevance of the tumor marker CA 19-9 in the diagnosing and monitoring of pancreatic carcinoma. Bull. Cancer., 77, 1990, 83-91.
25. SCHWARTZ, M.K.: Cancer markers. In: Cancer, Principles and Practice of Oncology. Eds: De Vita, V.T., Hellman, S., Rosenberg, S.A. Philadelphia, J.B. Lippincott 1993, 531-542.
26. SILVER, H.K.B., DENAULT, J., GOLD, P., THOMPSON, W.G., SHUSTER, J., FREEDMAN, S.A.: The detection of AFP in patients with viral hepatitis. Cancer Res., 34, 1974, 244-247.
27. SIMSEK, H., KADAYIFCI, A., OKAN, E.: High serum level of CA 125 in malignant peritoneal mesothelioma. Eur. J. Cancer, 31, 1995, 129.
28. SMTTH, J.B.: Occurence of alpha-fetoprotein in acute viral hepatitis. Int. J. Cancer, 8, 1971, 421-424.
29. STEINBERG, W.: The clinical utility of the CA 19-9 tumor-associated antigen. Am. J. Gastroenterol., 85, 1990, 350-355.
30. TAKAHASHI, K., SHIBUKAWA, T., MORIYAMA, M.: Clinical usefulness and falsepositive results of CA 125 as a tumor marker of ovarian cancer. Jpn. J. Surg., 16, 1986, 305-310.
31. TOROSIAN, M.H.: The clinical usefulness and limitations of tumor markers. Surg. Gynecol. Obst., 166, 1988, 567-579.
32. VAITUKATIUS, J.L., BRAUSTEIN, G.D., ROSS, G.T.: A radioimmunoassay which specifically measures human chorionic gonadotropin in the presence of human luteinizing hormone. Am. J. Obstet. Gynecol., 113, 1972, 751-758.